Mohamed Moamen El Barody has completed his M.B.B.Ch, M.Sc. at the age of 28 years from radiology department of Assuit University Hospital, Egypt. He is assistant lecturer of radiodiagnosis at radiology department of South Egypt Cancer Institute, Assuit University, Egypt. He has published 1 paper in medical journal of Cairo University.

South Egypt Cancer Institute, Assuit University, Egypt\r\n\r\n\r\nBiopsy plays an important role in the care of patients with a renal mass. As the biopsy results are used to confirm the diagnosis of renal cancers, metastases, and infections, and the biopsy can help subtype and grade many primary renal cancers. Use of percutaneous biopsy to identify which masses are benign, and in some patients which masses are more or less aggressive. It is essential to identify tumor histology in the setting of metastatic disease. Before image-guided biopsy, a cross-sectional imaging studies is needed to determine the safest approach to the targeted lesion, the shortest distance to the lesion without crossing additional organs, large vessels, or vital structures is optimal. CT guided biopsy has the advantage of better resolution and tissue contrast, Is better able to localize the lesion and the needle tip and identify the surrounding critical structures (pleural space and bowel). In the last 10 years there were little number of published articles about role of percutaneous biopsy in renal masses, Aim of our study: to evaluate the role of CT-guided percutaneous biopsy in diagnoses of different renal tumors either benign or malignant ( primary or secondary) masses. Twenty patients were included in this study, These patients were presented with renal tumor of indeterminate diagnoses according to the imaging modalities (US, CT or MRI), CT-guided percutaneous biopsy was performed to evaluate the nature of this renal tumor after pre and post contrast CT examination. Biopsy yield, complications and impact of patient`s management were analyzed. The diagnostic capability of CT-guided percutaneous biopsy was (90%), non representative biopsy was demonstrated in 2 patients (10%) who underwent 2nd trial of biopsy with incidence of minor complications (5%). Finally, The CT guided percutaneous biopsy can help in accurate and specific diagnosis of renal tumors with subsequent impact on their clinical management.\r\n

Hanan Selim is currently working as Assistant Professor of Clinical Oncology at Cairo University, Egypt. Her research experience includes various programs, contributions and participation at different countries for diverse fields of study. Her research interests reflect in her wide range of publications in various national and international journals. Her research fields of interest include Oncology, Clinical Oncology, etc.rnrn

Prognostic impact of hemoglobin level and other factors on outcome of elderly Egyptian patients with glioblastoma multiformernHanan SelimrnKasr Al Aini Hospital-Cairo University, EgyptrnrnAbstractrnrnBackground: Overall survival in glioblastoma multiforme (GBM) is usually less than 12 months and long-term survival is rare. The incidence is increasing among elderly patients. In Egypt, CNS tumors ranked as the 4th most common following liver, breast and bladder cancers. The importance of prognostic factors has grown because they could guide the treatment decision, especially for elderly patients. This retrospective study aimed to assess the impact of serum hemoglobin level among other factors on the survival of elderly GBM patients treated with radiotherapy. rnrnMethods: The medical records of 118 elderly GBM patients (≥60) years treated in NEMROCK Center from January 2010 to July 2016 were reviewed for the patient\'s characteristics, treatments modalities and survival rate.rnrnResults: The median age at diagnosis was 63 years (range 60- 75). Baseline hemoglobin level >12 g/dl was recorded in 62 (52.5%) patients. After a median follow-up of 6.5 months (range 2–18), the 6, 12 and 18- month survival rates were 66%, 12% and 5%, respectively. On multivariate analysis, biopsy alone (P=.031), pre-radiotherapy hemoglobin level <12g/dl (P=.013), not receiving adjuvant chemotherapy (P=.001), and age >65 years (P= 0.005) were independent predictors of reduced overall survival.rnrnConclusions: The current retrospective study demonstrated statistically significant negative impact of elderly age and pre-radiotherapy low hemoglobin level on outcomes of GBM elderly patients.rn

Hanan Selim is currently working as Assistant Professor of Clinical Oncology at Cairo University, Egypt. Her research experience includes various programs, contributions and participation at different countries for diverse fields of study. Her research interests reflect in her wide range of publications in various national and international journals. Her research fields of interest include Oncology, Clinical Oncology, etc.

AbstractrnrnBackground: Cholangiocarcinoma (CCA) is a rare malignant tumor and unfortunately, the prognosis of the patients is generally poor that increasing the need for effective cancer treatment. In Egypt, the incidence rate of biliary tract carcinoma varies by geographical stratum. Its incidence range between 0.3 in lower Egypt to 1.6 in upper Egypt and 710 new cases are the estimate for 2020 with female-to-male ratios 1.4. rnrnAim: Therefore the aim of this retrospective study was to review the epidemiological features and the impact of chemotherapy on our Egyptian patients with advanced CCA presented to our center.rnrnPatients & Methods: A total of 44 patients with advanced or metastatic CCA were treated with palliative chemotherapy from January 2005 to October 2016.rnrnResults: The median age was 53 years (range 31–75years), with female to male ratio 1.37. Hilar tumor was the most common site of the tumor in 50% of patients and 18 (40.9%) patients had advanced local disease. The median OS and PFS times of all patients were 9 and 7 months respectively. On univariant analysis, good performance status (P=0.009) and combined chemotherapy (P=0.001) were significantly correlated with long survival. Meanwhile, low bilirubin level (<5 mol/L) and treated with combined chemotherapy were significantly correlated with long PFS (P=0.004 and P=0.001 respectively). Combined treatment modalities is the only factor statistically associated with improved OS (HR 0.204 (95% CI, 0.041-1.003, P=0.05) and PFS (HR 0.148 (95% CI, 0.028-0.781) after multivariate analysis.rn